Company news
Ipsen Sa (EURONEXT:IPN) news
Ipsen Sa news releases on 6ix. Latest, Sep 28, 2026: IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026
Press releases & updates
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026
September 28, 2026
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 39 - 2026
September 27, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2026
September 22, 2026
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 38 - 2026
September 21, 2026
Ipsen appoints Mariette Finet to its Board of Directors
September 18, 2026
Ipsen nomme Mariette Finet administratrice au sein de son Conseil d’administration
September 17, 2026
Correction: IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026
September 15, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026
September 14, 2026
Ipsos: Kelly Beaver accelerates the execution of the Horizons strategic plan
September 14, 2026
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 37 - 2026
September 13, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2025
September 7, 2026
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 36 - 2025
September 6, 2026
Ipsen - August 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
September 3, 2026
Ipsen - Août 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
September 2, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2026
August 31, 2026
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 35 - 2026
August 30, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2026
August 24, 2026
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
August 21, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2026
August 17, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2026
August 10, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2026
August 3, 2026
Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance
July 30, 2026
Ipsen nominates Catherine Bradley to its Board of Directors as independent Director
July 29, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2026
July 27, 2026
Ipsen provides update on Phase III BOLD trial in biliary atresia
July 24, 2026
Ipsen - Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026
July 22, 2026
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline
July 22, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2026
July 21, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2026
July 15, 2026
Ipsen : IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb ELSPIRE study
July 13, 2026
Ipsen - Dysport is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine
July 10, 2026
Ipsen - June 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
July 9, 2026
Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.
July 9, 2026
Ipsen - Half year statement - 2026 06 30
July 7, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2026
July 6, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 26- 2026
July 3, 2026
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
July 1, 2026
Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
June 29, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026
June 22, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2026
June 15, 2026
Ipsen : welcomes the European Union’s publication of the Joint Clinical Assessment for Ojemda® (tovorafenib)
June 9, 2026
Ipsen - May 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
June 8, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2026
June 8, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2026
June 1, 2026
Ipsen announces the launch of an Employee Shareholding Plan
May 29, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 21 - 2026
May 27, 2026
National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare
May 20, 2026
Ipsen announces late-breaking data from first head-to-head study comparing Dysport and Botox in adults with upper limb spasticity
May 20, 2026
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
May 19, 2026
Ipsen - April 2026- Monthly information relative to the total number of voting rights and shares composing the share capital
May 18, 2026